EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

Robert S Rosenson, Daniel Gaudet, Robert A Hegele, Christie M Ballantyne, Stephen J Nicholls, Kathryn J Lucas, Javier San Martin, Rong Zhou, Ma'an Muhsin, Ting Chang, Jennifer Hellawell, Gerald F Watts und 1 weitere

New England Journal of Medicine · 12.09.2024 · 391 (10) · 913-925

DOI: 10.1056/nejmoa2404147 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.09.2024. Verfasst von Robert S Rosenson und 12 weiteren Autor:innen. Beteiligte Einrichtung: From the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York (R.S.R.); Université de …. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, Hyperlipidemias, RNAi Therapeutics, Triglycerides. Die Arbeit wurde bisher 228-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Arrowhead Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-Like Protein 3HyperlipidemiasRNAi TherapeuticsTriglyceridesRNA, Small InterferingAgedFemaleHumansMaleMiddle AgedCholesterol, LDLDose-Response Relationship, DrugDouble-Blind MethodInjections, SubcutaneousLiverTreatment Outcome

Substanzen

Angiopoietin-Like Protein 3ANGPTL3 protein, humanCholesterol, LDLTriglyceridesRNA, Small Interfering

Autor:innen und Institutionen

  • From the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York (R.S.R.); Université de Montréal, Montreal (D.G.), and Robarts Research Institute, London, ON…

Förderung

  • Arrowhead Pharmaceuticals

Zitieren

APA

Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., Hellawell, J., Watts, G. F., & ARCHES-2 Trial Team (2024). Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine, 391(10), 913-925. https://doi.org/10.1056/nejmoa2404147

Vancouver

Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. New England Journal of Medicine. 2024;391(10):913-925. doi:10.1056/nejmoa2404147

BibTeX
@article{Rosenson2024,
  author = {Rosenson, Robert S and Gaudet, Daniel and Hegele, Robert A and Ballantyne, Christie M and Nicholls, Stephen J and Lucas, Kathryn J and San Martin, Javier and Zhou, Rong and Muhsin, Ma'an and Chang, Ting and Hellawell, Jennifer and Watts, Gerald F and ARCHES-2 Trial Team, ARCHES-2 Trial Team},
  title = {Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {10},
  pages = {913--925},
  doi = {10.1056/nejmoa2404147}
}
Kostenlos starten →